Mark C Bagley Selected Research

Werner Syndrome (Werner's Syndrome)

4/2016	Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts.
1/2016	The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells.
6/2015	Microwave-Assisted Synthesis of a MK2 Inhibitor by Suzuki-Miyaura Coupling for Study in Werner Syndrome Cells.
1/2013	The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome.
12/2011	Investigating the role of c-Jun N-terminal kinases in the proliferation of Werner syndrome fibroblasts using diaminopyridine inhibitors.
9/2010	Gram-scale synthesis of the p38α MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome.
6/2010	Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome.
6/2010	Evaluating the role of p38 MAP kinase in growth of Werner syndrome fibroblasts.
2/2010	Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome.
2/2010	Microwave-assisted synthesis of a pyrazolyl ketone library for evaluation as p38 MAPK inhibitors in Werner syndrome cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark C Bagley Research Topics

Disease

14	Werner Syndrome (Werner's Syndrome) 04/2016 - 11/2006
2	Genomic Instability 06/2010 - 04/2007
1	COVID-19 01/2022
1	Neoplasms (Cancer) 03/2021
1	Adenocarcinoma 03/2021
1	Breast Neoplasms (Breast Cancer) 03/2021
1	Autoimmune Diseases (Autoimmune Disease) 12/2020
1	Polymorphic catecholergic ventricular tachycardia 01/2016

Drug/Important Bio-Agent (IBA)

10	p38 Mitogen-Activated Protein KinasesIBA 12/2020 - 09/2007
6	SB 203580IBA 01/2016 - 04/2007
5	Phosphotransferases (Kinase)IBA 12/2011 - 04/2007
4	5- amino- 1- (4- fluorophenyl)- 4- (3- (2,3- dihydroxypropoxy)benzoyl)pyrazoleIBA 01/2016 - 07/2008
3	KetonesIBA 01/2016 - 07/2008
3	VX-745IBA 09/2010 - 11/2009
2	MAP-kinase-activated kinase 2IBA 06/2015 - 01/2013
2	doramapimodIBA 06/2010 - 11/2006
1	teriflunomideIBA 01/2022
1	Antirheumatic Agents (DMARD)IBA 01/2022
1	Leflunomide (Arava)FDA LinkGeneric 01/2022
1	Histones (Histone)IBA 03/2021
1	Molecular Chaperones (Chaperone, Molecular)IBA 03/2021
1	carbazoleIBA 03/2021
1	CarbazolesIBA 03/2021
1	Flecainide (Tambocor)FDA LinkGeneric 01/2016
1	3-pyridinylboronic acidIBA 06/2015
1	2-chloroquinolineIBA 06/2015
1	AcidsIBA 06/2015
1	BromidesIBA 06/2015
1	Adenosine Triphosphate (ATP)IBA 09/2010
1	Biological ProductsIBA 06/2010
1	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2010
1	Therapeutic UsesIBA 02/2010
1	VX (EDIM)IBA 09/2007
1	Mitogen-Activated Protein Kinase 14IBA 11/2006
1	Urea (Carbamide)FDA LinkGeneric 11/2006
1	pyrazoleIBA 11/2006
1	CarbamatesIBA 11/2006

Therapy/Procedure

1	Therapeutics 12/2011